Regal Investment Advisors LLC Exelixis, Inc. Transaction History

Regal Investment Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$18.17 - $20.48 $206,683 - $232,960	-11,375 Reduced 38.38%	18,261 $348,000
Q1 2023 May 11, 2023	SELL	$16.3 - $19.41 $717 - $854	-44 Reduced 0.15%	29,636 $575,000
Q4 2022 Mar 01, 2023	BUY	$14.96 - $17.39 $658 - $765	44 Added 0.15%	29,680 $476,000
Q2 2022 Aug 09, 2022	SELL	$17.44 - $23.16 $36,536 - $48,520	-2,095 Reduced 6.6%	29,636 $617,000
Q2 2021 Aug 09, 2021	BUY	$17.95 - $25.56 $569,571 - $811,044	31,731 New	31,731 $578,000
Q1 2021 May 12, 2021	SELL	$20.53 - $25.22 $651,437 - $800,255	-31,731 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$18.39 - $24.8 $583,533 - $786,928	31,731 New	31,731 $637,000
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $666,214 - $868,303	-32,231 Closed	0 $0
Q2 2020 Aug 03, 2020	BUY	$16.46 - $27.42 $530,522 - $883,774	32,231 New	32,231 $765,000

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Regal Investment Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Regal Investment Advisors LLC with notifications on news.